Search company, investor...
TISSIUM company logo


Founded Year



Series D | Alive

Total Raised


Last Raised

$53.87M | 13 days ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+120 points in the past 30 days


TISSIUM is a medtech company developing biomorphic programmable polymers for tissue reconstruction. The company reconstructs damaged tissue and restores its natural function. TISSIUM was founded in 2013 and is based in Paris, France.

Headquarters Location

74 rue du Faubourg Saint Antoine

Paris, 75012,


+33 1 76 21 72 28

Missing: TISSIUM's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: TISSIUM's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing TISSIUM

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TISSIUM is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Advanced Materials

1,282 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.


Health IT

7,901 items


TISSIUM has filed 5 patents.

The 3 most popular patent topics include:

  • 3D printing
  • Biomaterials
  • Biomedical engineering
patents chart

Application Date

Grant Date


Related Topics




Adhesives, Implants (medicine), Cardiac surgery, Polymers, Congenital heart defects


Application Date


Grant Date



Related Topics

Adhesives, Implants (medicine), Cardiac surgery, Polymers, Congenital heart defects



Latest TISSIUM News

Tissium eyes commercial launch following €50m financing round

May 26, 2023

Tissium eyes commercial launch following €50m financing round Tissium hopes to commercialise its biomorphic polymer in 2024. Image credit: Tissium Tissue reconstruction company Tissium has secured $53.8m (€50m) in Series D financing round to launch its platform of biomorphic programmable polymers. The funds came from previous investors Cathay Health, Mutuel Innovation and Sofinnova Partners, as well as fresh investment from Fonds Stratégique des Transitions and Merieux Developpement. Recommended Reports Based in Paris, France and Boston, USA, the privately-owned company’s pipeline of seven products include sutureless nerve repair, hernia repair and cardiovascular sealants. Each product aims to enhance tissue reconstruction in unique ways. Christophe Bancel, CEO of Tissium said the round will be used to finance commercialisation of the company’s first products by 2024, as well as extending its product and platform pipeline further. “This funding significantly bolsters our ability to move with speed towards our goal of enhancing tissue reconstruction for patients. We look forward to continuing our work to bring innovation in the space and develop products that make a difference in patients’ lives,” said Bancel. Despite operating in a challenging funding environment, Bancel said Tissium’s in-house manufacturing of the technology and the wide range of its potential uses in atraumatic body repair had made it an attractive prospect for investors As Tissium expands its platform to new therapeutic areas, the company said it will focus on introducing their portfolio to the US market, with expansions into the EU and elsewhere planned further down the line. This follows recent successes in the ongoing first in-human study on Tissium’s COAPTIUM Connect, combining a 3D-printed implantable device and on-demand activated adhesive to achieve sutureless nerve repair. It is the first time Tissium has been used in a clinical study and will pave the way for future trials in the near term. Tissium’s 3D printing applications could prove extremely lucrative in the future, as the company hopes to co-develop novel surgical solutions with strategic partners. By providing cheaper, easily produced and personalised medical devices , 3D printing is expected to be one of the industry’s most valuable sectors in years to come. According to GlobalData analysis, medical and dental 3D printing revenue has been steadily increasing since 2018 and is set to continue until at least 2026. The Paris based company has benefitted from France’s strong medtech start-up landscape . Since 2020, Tissium has been a participant in the French Tech 120 program designed to support technology startups. French med tech will also benefit from the $8bn (€7.5bn) Health Innovation Plan 2030, with $2.5bn (€2.4bn) allocated to startups in the sector. Share this article

TISSIUM Frequently Asked Questions (FAQ)

  • When was TISSIUM founded?

    TISSIUM was founded in 2013.

  • Where is TISSIUM's headquarters?

    TISSIUM's headquarters is located at 74 rue du Faubourg Saint Antoine, Paris.

  • What is TISSIUM's latest funding round?

    TISSIUM's latest funding round is Series D.

  • How much did TISSIUM raise?

    TISSIUM raised a total of $209.63M.

  • Who are the investors of TISSIUM?

    Investors of TISSIUM include Sofinnova Partners, ISALT, Credit Mutuel Innovation, Merieux Equity Partners, Cathay Capital Private Equity and 14 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.